Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting

Etanercept Therapy in Patients with Psoriasis and Concomitant HCV Infection

(2017) M.C. Garavaglia et al.   INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY

The prevention of infection-associated cancers

(2011) S. De Flora et al.   CARCINOGENESIS

Hepatitis B Virus (HBV) Reactivation in Patients Receiving Tumor Necrosis Factor (TNF)-Targeted Therapy

(2011) Roberto Pérez-Alvarez et al.   MEDICINE

Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review

(2011) A. M. G. Brunasso et al.   RHEUMATOLOGY

A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study

(2010) D. Thaçi et al.   BRITISH JOURNAL OF DERMATOLOGY

Safety of anti-tumour necrosis factor-α agents in psoriasis patients who were chronic hepatitis B carriers: a retrospective report of seven patients and brief review of the literature

(2010) C Fotiadou et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Infliximab treatment for severe psoriasis in a patient with active hepatitis B virus infection

(2009) Alberto Conde-Taboada et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

European S3-Guidelines on the systemic treatment of psoriasis vulgaris

(2009) D Pathirana et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

The impact of treatment with tumour necrosis factor-α antagonists on the course of chronic viral infections: a review of the literature

(2008) S. Domm et al.   BRITISH JOURNAL OF DERMATOLOGY

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

(2008) Craig L Leonardi et al.   LANCET

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

(2008) Kim A Papp et al.   LANCET

Use of Tumor Necrosis Factor-α Inhibitors in Patients with Chronic Hepatitis B Infection

(2008) Matthew B. Carroll et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM